record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundtheoretical · manual state transition
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
theoretical
conditions
Provenance
source title
CONNECT TarGeT-D olutasidenib phase 2 pediatric HGG trial
authors
reviewer:will-blair
IDH1-mutant pediatric HGG (5-10% incidence, vs ~35% adult GBM) shows distinct molecular context and response to olutasidenib + TMZ; CONNECT TarGeT-D biomarker-driven enrollment demonstrates pediatric-specific precision trial architecture.
vs_be121dff87a8ab1a · manual_curation
outgoing
vf_26edfbefc6b5cbb8G207 mechanism (lytic immunity + oncolytic spread) succeeds where BIOMEDE targeted-kinase arms failed; mechanism matters
incoming
No incoming links.
events
vev_c161c26b33ba2c2bfinding.assertedManual finding added to frontier state
reviewer:will-blair · 2026-05-29
reviewable changes
vpr_1cd1be180e4e4c60finding.addManual finding added to frontier state
applied · reviewer:will-blair · 2026-05-29
evaluations
No evaluation record targets this finding id.